Navigation Links
Medarex to Receive Milestone Payment from Amgen
Date:12/18/2007

PRINCETON, N.J., Dec. 18 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it will receive a milestone payment for an undisclosed amount from its licensing partner, Amgen, for advancing an antibody into human clinical trials. The antibody was developed using Medarex's UltiMAb(R) technology and is the fifth UltiMAb-derived antibody in clinical development by Amgen, including two UltiMAb antibodies in Phase II clinical studies. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development and to the market.

"As a leading biotechnology company, Amgen continues to use its product development expertise to move UltiMAb-derived antibodies into clinical development and potentially toward commercialization," said Howard H. Pien, President and CEO of Medarex. "We are pleased by the advancements made by Amgen with UltiMAb antibodies and look forward to their continued progress."

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , Isansys  Lifecare, a new generation ... Engine wireless patient monitoring platform, as it ships more systems ... , Scotland and Norway ... generation system, launched earlier this year, is now being used in ... , This new technology significantly enhances the user experience ...
(Date:5/31/2016)... 2016 194 Mitgliedsstaaten ... Eliminierung von viraler Hepatitis    Am ... eingegangen, virale Hepatitis bis 2030 zu eliminieren. ... Assembly haben sich die Staaten einstimmig dafür entschieden, ... Viral Hepatitis Strategy) zu verabschieden, was das bisher ...
(Date:5/31/2016)... May 31, 2016 RnRMarketResearch.com adds ... with comparative analysis of Asthma therapy at various stages, ... route of administration (RoA) and molecule type, along with ... also reviews key players involved in the therapeutic development ... projects. Complete report on H1 2016 pipeline ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... technology solutions to the healthcare industry, The University of Scranton is adding a ... accelerated path to a career in rapidly growing field of healthcare information. ...
(Date:5/30/2016)... ... ... As the CDC relaxes its stance on traditional No-Nit policies, parents wonder ... lice free. , According to a May 26 article from news source ... classroom despite the fact that they may be harboring an infestation. Previous No-Nit policies ...
(Date:5/30/2016)... , ... May 30, 2016 , ... ... 6th, while Shaolin warrior 8-day-8 and 8-night special intensive summer training camp starts ... annual overnight summer camp offers families and children a fun and unique experience ...
(Date:5/29/2016)... North Carolina (PRWEB) , ... May 29, 2016 , ... ... Now, via Amazon.com, their new KlipPro KP-240L clipper is available to the public. This ... which is substantially wider than the average clipper. , Everything about this product ...
(Date:5/28/2016)... ... ... "Color Grading media can be time consuming but with FCPX LUT Night ... Austin - CEO of Pixel Film Studios. , With the FCPX LUT Night ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ...
Breaking Medicine News(10 mins):